Skip to main content
main-content

The independent medical news service

Lung cancer

13-02-2020 | Oncology | News | Article

Follow-up testing, treatment missing after first-line advanced NSCLC EGFR-TKI therapy

US researchers highlight the need for follow-up of stage IV non-small-cell lung cancer patients who receive first-line EGFR–tyrosine kinase inhibitor therapy, finding few patients subsequently undergo testing for the T790M mutation.

10-02-2020 | Oncology | News | Article

ASCO/Ontario Health update released for stage IV NSCLC without driver alterations

Read more here on these evidence-based guidelines

06-02-2020 | Oncology | News | Article

Patient video improves informed decision-making for lung cancer screening

Use of a patient decision aid video improves informed decision-making about lung cancer screening among people accessing smoking cessation services in the USA, study findings indicate.

05-02-2020 | Oncology | News | Article

Antibiotics, PPIs may adversely affect immunotherapy outcomes

Individuals receiving atezolizumab for advanced non-small-cell lung cancer may have worse survival if they are also taking antibiotics or proton pump inhibitors, indicates an analysis of the POPLAR and OAK trials.

31-01-2020 | Oncology | News | Article

NELSON: Low-dose CT screening reduces lung cancer mortality

Individuals at high risk for developing lung cancer benefit from periodic screening with low-dose computed tomography, indicate the 10-year results from the NELSON trial.

30-01-2020 | Oncology | News | Article

Lenvatinib plus pembrolizumab shows promise for RCC and other solid tumors

Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.

29-01-2020 | Oncology | News | Article

QoL, safety data boost evidence for atezolizumab–chemotherapy regimen in ES-SCLC

Adding atezolizumab to carboplatin plus etoposide does not lead to substantially more adverse events than placebo and does not adversely affect health-related quality of life in patients with extensive-stage small-cell lung cancer, IMpower 133 trial data show.

27-01-2020 | Oncology | News | Article

Surveillance recommendations published for NSCLC, SCLC after curative therapy

Click through to read more on this ASCO guideline

21-01-2020 | Oncology | News | Article

Age no bar for treatment selection in older NSCLC patients

Age should not be a selection factor for treatment decisions in older individuals with non-small-cell lung cancer, suggest two studies published in Cancer.

20-01-2020 | Oncology | News | Article

Crizotinib active against NSCLC with MET exon 14 alterations

The multikinase inhibitor crizotinib elicits responses and is well tolerated in people with non-small-cell lung cancer positive for MET exon 14 mutations, shows the PROFILE 1001 trial.

15-01-2020 | Oncology | News | Article

High BMI linked to improved survival with atezolizumab in advanced NSCLC patients

Being overweight or obese is associated with favorable survival outcomes in advanced non-small cell lung cancer patients treated with atezolizumab, research published in JAMA Oncology suggests.

09-01-2020 | Oncology | News | Article

Osimertinib a potential option for NSCLC with uncommon EGFR mutations

Individuals with advanced non-small-cell lung cancer harboring uncommon EGFR mutations have favorable outcomes in response to osimertinib treatment, say Korean researchers.

08-01-2020 | Oncology | News | Article

PD-1 inhibition may result in better solid tumor survival than PD-L1 inhibition

Treatment with PD-1 inhibitors offers better overall survival, with comparable tolerability, than does treatment with PD-L1 inhibitors for patients with solid tumors such as non-small-cell lung cancer, suggests a systematic review and meta-analysis.

02-01-2020 | Oncology | News | Article

Early promise with ganetespib not replicated in phase 3 lung adenocarcinoma trial

Adding the potent heat shock protein 90 inhibitor ganetespib to docetaxel does not improve survival among patients with advanced-stage lung adenocarcinoma when used in a second-line setting, results of the GALAXY-2 trial show.

20-12-2019 | Oncology | News | Article

J-FORCE supports olanzapine 5 mg addition to standard antiemetic therapy

Adding olanzapine 5 mg to standard aprepitant, palonosetron, and dexamethasone antiemetic therapy significantly reduces the number of patients vomiting and needing rescue medication following cisplatin-based chemotherapy, Japanese researchers report.

19-12-2019 | Oncology | News | Article

Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases

Patients with EGFR-mutant non-small-cell lung cancer and leptomeningeal metastases respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest.

17-12-2019 | Oncology | News | Article

TAPPS shows no difference in outcomes by talc delivery method

Individuals with malignant pleural effusion undergoing talc pleurodesis have comparable outcomes regardless of how the talc is delivered, shows a phase 3 trial reported in JAMA.

13-12-2019 | Oncology | News | Article

Sarcopenia could predict the immune-related toxicity risk associated with nivolumab

Sarcopenia in cancer patients taking nivolumab is associated with an increased risk for immune-related acute limiting toxicity, independent of plasma nivolumab concentrations, study results suggest.

06-12-2019 | Oncology | News | Article

FDA approves atezolizumab combination for metastatic NSCLC

Click through for more information on this approval

05-12-2019 | Oncology | News | Article

Adding pembrolizumab to chemotherapy boosts HRQoL in metastatic NSCLC

Previously untreated patients with stage IV squamous non-small-cell lung cancer report an improved health-related quality of life if carboplatin plus paclitaxel or nab-paclitaxel is supplemented with pembrolizumab, KEYNOTE-407 study results suggest.

Image Credits